Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IROCAS
2024-517489-41-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of irinotecan, oxaliplatin, fluorouracil and folinic acid in colon adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Disease-free survival at 3 years. Planned start Oct 2024; status: authorised.
02
Drugs
irinotecanoxaliplatinfluorouracilfolinic acid
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on 2024-517489-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517489-41-00.